Literature DB >> 30477880

High reproducibility is attainable in assessing histoprognostic parameters of pT1 colorectal cancer using routine histopathology slides and immunohistochemistry analyses.

Fanny Barel1, Anaïs Auffret2, Mélanie Cariou3, Tiphaine Kermarrec3, Laura Samaison4, Amélie Bourhis1, Bogdan Badic5, Julien Jézéquel2, Franck Cholet2, Jean-Pierre Bail5, Pascale Marcorelles1, Jean-Baptiste Nousbaum6, Michel Robaszkiewicz6, Laurent Doucet1, Arnaud Uguen7.   

Abstract

Assessment of the risk of lymph node invasion and tumour recurrence is critical to determine whether additional surgery is required in patients with endoscopically-removed pT1 colorectal cancer (CRC). A reproducible assessment of this risk of recurrence based on histopathological parameters is crucial for relevant therapeutic decisions. The inter-observer reproducibility of these parameters was the subject of our study. Two pathologists independently analysed 163 endoscopically-removed pT1 CRC recorded in a local digestive cancer registry database (Finistère, France). Using haematoxylin-eosin-saffron (HES) and immunohistochemistry slides, they evaluated several parameters related to the risk of tumour recurrence according to the international pT1 CRC-dedicated guidelines. Based on Kappa and intra-class correlation coefficients, good to very good inter-observer agreement was obtained by analysing vertical and lateral margins, submucosal invasion, tumour differentiation and lymphovascular invasion. The reproducibility of tumour budding quantification was only fair on the basis of HES slides but reached a very good agreement using cytokeratin immunohistochemistry. Dual colour cytokeratin and podoplanin immunohistochemistry also improved inter-observer agreement for the detection of lymphovascular invasion. All patients with loco-regional nodal metastases (7 of 101 who underwent complementary surgery) or distant metastases (3 patients) were diagnosed as having a high risk of recurrence and requiring an additional surgery by the two observers. Our study showed that good to very good inter-observer agreement is achievable in evaluating the pathological parameters of recurrence risk in endoscopically-removed pT1 CRC. In addition to HES slides, the detection of lymphovascular invasion and tumour budding can benefit with more reproducible immunohistochemical analyses.
Copyright © 2018 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Early colorectal cancer; immunohistochemistry; lymphovascular invasion; reproducibility; tumour budding

Mesh:

Substances:

Year:  2018        PMID: 30477880     DOI: 10.1016/j.pathol.2018.10.007

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  4 in total

1.  Utility of artificial intelligence with deep learning of hematoxylin and eosin-stained whole slide images to predict lymph node metastasis in T1 colorectal cancer using endoscopically resected specimens; prediction of lymph node metastasis in T1 colorectal cancer.

Authors:  Joo Hye Song; Yiyu Hong; Eun Ran Kim; Seok-Hyung Kim; Insuk Sohn
Journal:  J Gastroenterol       Date:  2022-07-08       Impact factor: 6.772

2.  The Importance of Being "That" Colorectal pT1: A Combined Clinico-Pathological Predictive Score to Improve Nodal Risk Stratification.

Authors:  Alessandro Gambella; Enrico Costantino Falco; Giacomo Benazzo; Simona Osella-Abate; Rebecca Senetta; Isabella Castellano; Luca Bertero; Paola Cassoni
Journal:  Front Med (Lausanne)       Date:  2022-02-14

3.  Establishment of a Dynamic Nomogram for Predicting the Risk of Lymph Node Metastasis in T1 Stage Colorectal Cancer.

Authors:  Zitao Liu; Chao Huang; Huakai Tian; Yu Liu; Yongshan Huang; Zhengming Zhu
Journal:  Front Surg       Date:  2022-03-21

4.  Poorly differentiated cluster grade-a vital predictor for lymph node metastasis and oncological outcomes in patients with T1 colorectal cancer: a retrospective study.

Authors:  Xiaolin Ji; Mei Kang; Xianzhi Zhao; Xiaoyu Li; Yingjie Guo; Ping Xie; Yanan Yu; Zibin Tian
Journal:  BMC Gastroenterol       Date:  2022-09-05       Impact factor: 2.847

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.